[Clinical applications of molecular biomarkers in urothelial carcinoma of bladder].
liang_cheng@yahoo.com
Liang
L
Cheng
Jia-wen
JW
Xu
Jia-jia
JJ
He
Jing
J
Zhao
Xiao-dong
XD
Teng
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D051926:Basigin / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D020869:Gene Expression Profiling; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D051034:Inhibitor of Apoptosis Proteins / Q000032:analysis; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000378:metabolism*; D009687:Nuclear Proteins / Q000032:analysis; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000032:analysis / Q000235:genetics; D000077022:Survivin; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*
C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D009687:Nuclear Proteins; D000077022:Survivin; D016159:Tumor Suppressor Protein p53; C100379:nuclear matrix protein 22; D051926:Basigin; D051498:Receptor, Fibroblast Growth Factor, Type 3